BioPharma Credit (LSE:BPCR) generates its income in a straightforward way: it lends money to life-sciences companies, mostly through senior secured loans, and passes the interest it earns to shareholders as dividends. The London-listed Investment trust, advised by the US specialist Pharmakon Advisors, targets a base Dividend of 7 US cents a share a year and has topped that up with special payouts when Earnings allow.

The model has been busy in 2026. Since March the trust has announced new loans to Zenas BioPharma, Mineralys Therapeutics, Idorsia, Kestra Medical and the ARCHIMED-backed Acquisition of Esperion, while also closing out its long-running LumiraDx exposure. That flurry of deals matters because the company ended 2025 with an unusually large cash pile after heavy repayments, and cash earns less than its loans do.

Half-year results for the six months to 30 June 2026 were published on 24 September, with an investor presentation on 25 September.

A Lender to Drug and Device Makers

BioPharma Credit invests in Debt backed by approved, revenue-generating pharmaceutical and medical-technology products rather than early-stage science. It launched on 27 March 2017. It sits in the direct lending segment of the investment trust market, with Pedro Gonzalez de Cosio, Pablo Legorreta and Martin Friedman named as fund managers.

Most loans are floating-rate. Recent deals typically pay three-month SOFR plus a Margin of between 5.50 and 5.75 percentage points, subject to a SOFR floor of 3.25 per cent, plus one-off fees when tranches are funded and further payments if borrowers repay early. That structure means income can rise when US rates are high and is partly protected by the floors when they fall. It often lends alongside a sister vehicle, BioPharma Credit Investments V.

A Year of Repayments, Then Redeployment

The Annual Report for the year to 31 December 2025, published on 24 March 2026, showed how repayments shape the business. The trust received $616.6 million of repayments in 2025, including a $261.4 million repayment from Collegium in December, while deploying $301.3 million into new investments. As a result, cash stood at $422.3 million, or 36.7 per cent of net assets, at the year end.

Even so, 2025 was a strong year for earnings. Net Income rose to 11.40 cents a share from 9.99 cents in 2024, and Net Asset Value (NAV) per share edged up to $1.0192 from $0.9963. Total dividends for 2025 came to 9.95 cents, including a 1.45-cent special paid in March 2026. At the end of 2025 the largest positions were Insmed (18.9 per cent of net assets), Novocure (8.5 per cent) and Evolus (5.4 per cent).

The investment manager pointed to an expanding pipeline as new products and companies come to market from 2026.

The 2026 Deal Flow

Much of this year's activity has been about putting that Cash Back to work:

  • Zenas BioPharma (March): up to $125 million across five tranches, maturing in March 2031, with $37.5 million funded initially.
  • Paratek (March): a $50 million investment tied to its Merger with Radius Health, after an earlier $25 million Loan was repaid with about $2 million in fees and interest.
  • Mineralys Therapeutics (June): up to $150 million, with $30 million funded at closing and further tranches linked to regulatory and sales milestones.
  • Idorsia (June): CHF 75 million in three tranches, with the Swiss franc portion at a fixed 7 per cent.
  • ARCHIMED/Esperion (July): a $120 million share of a $400 million facility, fully funded when the acquisition closed on 13 July 2026.
  • Kestra Medical (July): up to $45 million to the wearable-defibrillator maker, with $22.5 million funded at signing.

In August the trust completed the sale of its indirect interest in Lumira SAS in Colombia. It said that, together with earlier sales and interest received, it had recovered about 101 per cent of its original $419 million LumiraDx investment, before wind-down costs.

Dividends, Buybacks and the Discount

On 19 June 2026 the board declared a quarterly dividend of 1.75 cents for the quarter to 30 June, paid on 31 July. The company states that its policy is a 7-cent base annual dividend paid in four instalments, with special dividends usually in the fourth quarter, and occasionally the third, when the board considers them appropriate. Payments are designated as interest distributions for UK tax purposes.

The shares have spent long periods trading below NAV. The discount was 10.1 per cent at the end of 2025, and during that year the company bought back 56.8 million shares at an average of 86.9 cents. The gap appears to have narrowed since then: the unaudited NAV was 100.63 cents at 31 July 2026, the share price was 95.40 cents on 18 June, and the shares more recently stood at a discount of about 4.6 per cent with a Dividend Yield of around 7.2 per cent. Ongoing charges are 1.18 per cent, and the trust has no gearing.

Risks Behind the Yield

The income depends on borrowers continuing to pay. Many are single-product or early-commercial companies, so a disappointing launch, a pricing change or a regulatory setback could affect their ability to service debt. The LumiraDx episode showed that recoveries can take years. Concentration is also a factor, with a small number of loans making up a large share of the portfolio.

The company has noted that its borrowers depend heavily on US government reimbursement programmes, which leaves them exposed to changes in US drug-pricing policy. Falling US interest rates would reduce floating-rate income, although the SOFR floors provide a cushion. Early repayments bring fees but can also leave the trust holding low-yielding cash until it finds new loans, which is what happened at the end of 2025.

What to Watch Next

The key near-term item is the detail in the interim results released on 24 September: how much of the cash pile has been deployed, the level of net income per share compared with the 7-cent target, and any update on the Esperion, Kestra and Mineralys facilities. Beyond that, watch for further Tranche drawdowns linked to regulatory approvals, any new repayments, the fourth-quarter dividend and whether the board declares another special, and the monthly NAV announcements.

The Bottom Line

BioPharma Credit's income comes from a focused set of secured, mostly floating-rate loans to companies with approved products, supported by fees and a stated 7-cent base dividend. In 2026 it has been redeploying the large cash balance left by heavy 2025 repayments into new facilities. The main risks are borrower concentration, US healthcare policy and interest-rate direction, and investors will look to the latest interim figures for evidence that the new loans are replacing the income from repaid ones.